The future of psychedelic medicines and healt...

In a society that grows ever more risk averse, how do we balance fun and competition with our responsibilities to keep one another safe? In this talk, sport science professor Ben Jones explores our assumptions about contact sports. He reflects on our perceptions of risk and rewar ...  Show more

Dr. Alicia Zhou is the Chief Executive Officer of the Cancer Research Institute—the oldest nonprofit in the world devoted exclusively to cancer immunology and immunotherapy. She joins Shoshana to discuss the innovations happening in cancer research, how immunotherapy is different ...  Show more

This episode I discuss medical research on psychedelic compounds with Dr. Matthew Johnson, Ph.D., Professor of Psychiatry and Behavioral Sciences at Johns Hopkins School of Medicine. We discuss the biology and medical clinical-trial uses of psilocybin, MDMA, ayahuasca, DMT, and L ...  Show more

Psychiatrist and psychedelics and bipolar researcher Dr. Josh Woolley (University of California San Francisco), and peer researcher Amir speak on psilocybin, ketamine, and psychedelics and their links with bipolar disorder, and what the science says about psychedelics as treat ...

When psychedelics were first studied more than 50 years ago, researchers noticed that they were useful in helping people explore a greater sense of self. Now, after a half-century hiatus, scientists are studying psychedelics like MDMA, psilocybin, and ketamine as treatment for de ...  Show more

When psychedelics were first studied more than 50 years ago, researchers noticed that they were useful in helping people explore a greater sense of self. Now, after a half-century hiatus, scientists are studying psychedelics like MDMA, psilocybin, and ketamine as treatment for de ...  Show more